Capturing the holistic value of biosimilars in Europe – part 1: a historical perspective-Reference-Cited by-同舟云学术

Capturing the holistic value of biosimilars in Europe – part 1: a historical perspective

Published:2024-01-10 Issue:2 Volume:24 Page:237-250
ISSN:1473-7167
Container-title:Expert Review of Pharmacoeconomics & Outcomes Research
language:en
Short-container-title:Expert Review of Pharmacoeconomics & Outcomes Research

Author:

Mestre-Ferrandiz Jorge¹,Czech Marcin²,Smolen Josef S.³,Cornes Paul⁴,Aapro Matti S.⁵,Danese Silvio⁶,Deitch Stephen⁷,Tyldsley Hannah⁷,Foster Will⁷,Shah Pooja⁸,Latymer Mark⁹,Vulto Arnold G.¹⁰

Affiliation:

1. Department of Economics, Universidad Carlos III, Madrid, Spain

2. Department of Pharmacoeconomics, Institute of Mother and Child, Warsaw, Poland

3. Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria

4. Comparative Outcomes Group, Bristol, UK

5. Cancer Center, Clinique de Genolier, Vaud, Switzerland

6. Gastroenterology and Endoscopy, IRCCS Ospedale San Raffaele and University Vita-Salute San Raffaele, Milan, Italy

7. Life Science Practice, Charles River Associates, London, UK

8. US Medical Affairs, Pfizer, Collegeville, PA, USA

9. Global Medical Affairs, Biosimilars Portfolio, Pfizer, Sandwich, UK

10. Hospital Pharmacy, Erasmus University Medical Center, Rotterdam, Netherlands

Funder

Pfizer

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737167.2023.2297926

Reference80 articles.

1. Developments in therapy with monoclonal antibodies and related proteins

2. Troein P Newton M Scott K et al. The impact of biosimilar competition in Europe 2021. [updated 2021 Dec; cited 2023 May 30]. Available from: https://www.iqvia.com/-/media/iqvia/pdfs/library/white-papers/the-impact-of-biosimilar-competition-in-europe-2021.pdf

3. Financial toxicity and cancer treatments: Help from biosimilars – The explanatory case of bevacizumab

4. European Medicines Agency and European Commission. Biosimilars in the EU: information guide for healthcare professionals 2019. [updated 2019 Oct 10

5. cited 2023 May 30]. Available from: https://www.ema.europa.eu/en/documents/leaflet/biosimilars-eu-information-guide-healthcare-professionals_en.pdf

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Successful implementation of interchange of biologic medications in chronic arthritis after information of costs to prescribers;Exploration of Musculoskeletal Diseases;2024-09-10

3. Leveraging the holistic benefits of biosimilars in Europe – part 2: how payers can safeguard the future of a healthy biosimilar market environment;Expert Review of Pharmacoeconomics & Outcomes Research;2024-02-12